Agreement reached with the Agency on eteplirsen open-label confirmatory studies with enrollment of a broader base of DMD patients later this year; CAMBRIDGE, Mass.-- --Sarepta Therapeutics, Inc. , a developer of innovative RNA-based therapeutics, today announced it plans to submit a New Drug Application to the U.S. Food and Drug Administration by ... (more)
http://ift.tt/1h4AXoZ
http://ift.tt/1h4AXoZ
No comments:
Post a Comment